Vaccination Against Chlamydia Genital Infection Utilizing the Murine C. Muridarum Model

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2010 Nov 17

PMID 21078844

Citations 74

Authors

Christina M Farris

Richard P Morrison

Affiliations

Soon will be listed here.

Abstract

Chlamydia trachomatis genital infection is a worldwide public health problem, and considerable effort has been expended on developing an efficacious vaccine. The murine model of C. muridarum genital infection has been extremely useful for identification of protective immune responses and in vaccine development. Although a number of immunogenic antigens have been assessed for their ability to induce protection, the majority of studies have utilized the whole organism, the major outer membrane protein (MOMP), or the chlamydial protease-like activity factor (CPAF). These antigens, alone and in combination with a variety of immunostimulatory adjuvants, have induced various levels of protection against infectious challenge, ranging from minimal to nearly sterilizing immunity. Understanding of the mechanisms of natural infection-based immunity and advances in adjuvant biology have resulted in studies that are increasingly successful, but a vaccine licensed for use in humans has not yet been brought to fruition. Here we review immunity to chlamydial genital infection and vaccine development using the C. muridarum model.

Citing Articles

Structural Assessment of Major Outer Membrane Protein (MOMP)-Derived Vaccine Antigens and Immunological Profiling in Mice with Different Genetic Backgrounds.

Roe S, Zhu T, Slepenkin A, Berges A, Fairman J, de la Maza L Vaccines (Basel). 2024; 12(7).

PMID: 39066427 PMC: 11281497. DOI: 10.3390/vaccines12070789.

Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.

Poston T, Girardi J, Polson A, Bhardwaj A, Yount K, Jaras Salas I Mucosal Immunol. 2024; 17(5):1005-1018.

PMID: 38969067 PMC: 11495396. DOI: 10.1016/j.mucimm.2024.06.012.

In silico design and analysis of a multiepitope vaccine against Chlamydia.

Tanner T, Medhavi F, Richardson S, Omosun Y, Eko F Pathog Dis. 2024; 82.

PMID: 38889932 PMC: 11234648. DOI: 10.1093/femspd/ftae015.

Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.

Slepenkin A, Pal S, Rasley A, Coleman M, de la Maza L NPJ Vaccines. 2024; 9(1):104.

PMID: 38858418 PMC: 11164897. DOI: 10.1038/s41541-024-00880-6.

Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum....

de la Maza L, Slepenkin A, Pal S, Rasley A, Coleman M Res Sq. 2024; .

PMID: 38168233 PMC: 10760204. DOI: 10.21203/rs.3.rs-3688658/v1.

References

OConnell C, Ingalls R, Andrews Jr C, Scurlock A, Darville T . Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol. 2007; 179(6):4027-34. DOI: 10.4049/jimmunol.179.6.4027. View

Hafner L, Beagley K, Timms P . Chlamydia trachomatis infection: host immune responses and potential vaccines. Mucosal Immunol. 2008; 1(2):116-30. DOI: 10.1038/mi.2007.19. View

Roan N, Starnbach M . Immune-mediated control of Chlamydia infection. Cell Microbiol. 2007; 10(1):9-19. DOI: 10.1111/j.1462-5822.2007.01069.x. View

Zhang Y, Stewart S, Caldwell H . Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect Immun. 1989; 57(2):636-8. PMC: 313145. DOI: 10.1128/iai.57.2.636-638.1989. View

Olivares-Zavaleta N, Whitmire W, Gardner D, Caldwell H . Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection. Vaccine. 2009; 28(6):1454-62. PMC: 2821993. DOI: 10.1016/j.vaccine.2009.11.073. View

Tuffrey M, Alexander F, Taylor-Robinson D . Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J Exp Pathol (Oxford). 1990; 71(3):403-10. PMC: 1998699. View

Murthy A, Chambers J, Meier P, Zhong G, Arulanandam B . Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2006; 75(2):666-76. PMC: 1828486. DOI: 10.1128/IAI.01280-06. View

Morrison S, Morrison R . Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun. 2001; 69(4):2643-9. PMC: 98202. DOI: 10.1128/IAI.69.4.2643-2649.2001. View

Sun G, Pal S, Weiland J, Peterson E, de la Maza L . Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009; 27(36):5020-5. PMC: 2741729. DOI: 10.1016/j.vaccine.2009.05.008. View

10.

Rockey D, Wang J, Lei L, Zhong G . Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines. 2009; 8(10):1365-77. DOI: 10.1586/erv.09.98. View

11.

Ramsey K, DeWolfe J, Salyer R . Disease outcome subsequent to primary and secondary urogenital infection with murine or human biovars of Chlamydia trachomatis. Infect Immun. 2000; 68(12):7186-9. PMC: 97838. DOI: 10.1128/IAI.68.12.7186-7189.2000. View

12.

Chaganty B, Murthy A, Evani S, Li W, Guentzel M, Chambers J . Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010; 28(11):2323-9. PMC: 2846592. DOI: 10.1016/j.vaccine.2009.12.064. View

13.

Wang J, Chen L, Chen F, Zhang X, Zhang Y, Baseman J . A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. Vaccine. 2009; 27(22):2967-80. PMC: 2680781. DOI: 10.1016/j.vaccine.2009.02.095. View

14.

Ekong E, Okenu D, Mania-Pramanik J, He Q, Igietseme J, Ananaba G . A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol Med Microbiol. 2008; 55(2):280-91. PMC: 3062614. DOI: 10.1111/j.1574-695X.2008.00493.x. View

15.

Su H, Messer R, Whitmire W, Hughes S, Caldwell H . Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains. Infect Immun. 1999; 68(1):192-6. PMC: 97120. DOI: 10.1128/IAI.68.1.192-196.2000. View

16.

Perry L, Su H, Feilzer K, Messer R, Hughes S, Whitmire W . Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-gamma-mediated inhibition. J Immunol. 1999; 162(6):3541-8. View

17.

Hickey D, Jones R, Bao S, Blake A, Skelding K, Berry L . Intranasal immunization with C. muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate. Vaccine. 2004; 22(31-32):4306-15. DOI: 10.1016/j.vaccine.2004.04.021. View

18.

Huang Z, Feng Y, Chen D, Wu X, Huang S, Wang X . Structural basis for activation and inhibition of the secreted chlamydia protease CPAF. Cell Host Microbe. 2008; 4(6):529-42. DOI: 10.1016/j.chom.2008.10.005. View

19.

Cunningham K, Carey A, Hafner L, Timms P, Beagley K . Chlamydia muridarum major outer membrane protein-specific antibodies inhibit in vitro infection but enhance pathology in vivo. Am J Reprod Immunol. 2010; 65(2):118-26. DOI: 10.1111/j.1600-0897.2010.00894.x. View

20.

Barron A, WHITE H, Rank R, Soloff B, MOSES E . A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis. J Infect Dis. 1981; 143(1):63-6. DOI: 10.1093/infdis/143.1.63. View